Published in

American Association for the Advancement of Science, Science, 6330(355), p. 1206-1211, 2017

DOI: 10.1126/science.aag1006

Links

Tools

Export citation

Search in Google Scholar

Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420

Journal article published in 2017 by Nicolas Blondiaux ORCID, Martin Moune ORCID, Matthieu Desroses ORCID, Rosangela Frita ORCID, Marion Flipo ORCID, Vanessa Mathys, Karine Soetaert, Mehdi Kiass, Vincent Delorme ORCID, Kamel Djaout ORCID, Vincent Trebosc ORCID, Christian Kemmer, René Wintjens ORCID, Alexandre Wohlkonig ORCID, Rudy Antoine and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Countering TB prodrug resistance The arsenal of antibiotics for treating tuberculosis (TB) contains many prodrugs, such as ethionamide, which need activation by normal metabolism to release their toxic effects. Ethionamide is potentiated by small molecules. Blondiaux et al. screened for more potent analogs and identified a lead compound called SMARt-420. This small molecule inactivates a TetR-like repressor, EthR2, and boosts ethionamide activation. SMARt-420 successfully promoted clearance of multidrug-resistant strains of Mycobacterium tuberculosis from the lungs of mice. Science , this issue p. 1206